Juliane Etima, Ariana W K Katz, Zoe Duby, Morgan Garcia, Thesla Palanee-Phillips, Krishnaveni Reddy, Florence Mathebula, Chifundo Zimba, Leila E Mansoor, Devika Singh, Elmah Manengamambo, Sarita Naidoo, Lydia Soto-Torres, Elizabeth T Montgomery
As demonstrated by the Phase III clinical trial, MTN-020/ASPIRE, the monthly dapivirine vaginal ring is well tolerated and reduces the risk of HIV-1 as a woman-initiated prevention option. This analysis uses data from the follow-on MTN-032/Assessment of ASPIRE and HOPE Adherence (AHA) qualitative study to understand how perceptions (or misperceptions) of ring efficacy may have influenced behavior during ASPIRE, and affected intention to use the ring in future ring projects, specifically HOPE, the planned open-label extension study...
November 2, 2021: AIDS and Behavior